Table 2.

In vitro susceptibilities to fluconazole, itraconazole, and BMS-207147 of bloodstream isolates of Candida spp. from 1997 and 1998

Species (no. of isolates tested) and antifungal agentMIC (μg/ml)% Rc
50%a90%b
C. albicans (341)
 Fluconazole0.250.50.9
 Itraconazole0.030.121.5
 BMS-2071470.0070.03
C. glabrata(106)
 Fluconazole8165.7
 Itraconazole0.5234.9
 BMS-2071470.251
C. parapsilosis (97)
 Fluconazole0.520
 Itraconazole0.120.250
 BMS-2071470.030.06
C. tropicalis(49)
 Fluconazole0.520
 Itraconazole0.120.254.1
 BMS-2071470.030.12
C. guilliermondii (10)
 Fluconazole240
 Itraconazole0.25120
 BMS-2071470.120.25
C. krusei (10)
 Fluconazole3264100
 Itraconazole0.5240
 BMS-2071470.250.5
 Total (613)
 Fluconazole0.581.8
 Itraconazole0.060.58.2
 BMS-2071470.0150.25
  • a 50%, MIC50.

  • b 90%, MIC90.

  • c Based on NCCLS breakpoints (7). All C. krusei isolates are considered fluconazole R.